Cargando…

Dolutegravir plus rilpivirine: benefits beyond viral suppression: DORIPEX retrospective study

Switching dual therapy with dolutegravir (DTG) plus rilpivirine (RPV) was assessed in the SWORD-1 and SWORD-2 studies. Real-life data regarding the immunological impact of this approach on CD4+ and CD8+ T lymphocyte counts and the CD4/CD8 ratio are scarce. We evaluated this strategy on the basis of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Troya, Jesús, Dueñas, Carlos, Irazola, Idoia, de los Santos, Ignacio, de la Fuente, Sara, Gil, Desiré, Hernández, Cristina, Galindo, María José, Gómez, Julia, Delgado, Elisabeth, Moreno-García, Estela, Posada, Guillermo, Aldámiz, Teresa, Iribarren, Jose Antonio, Guerra, José Manuel, Morán, Miguel Ángel, Galera, Carlos, Fuente, Javier, Peláez, Ana, Cervero, Miguel, Garcinuño, María, Montero, Marta, Ceballos, Francisco, Buzón, Luis
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	4850
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9276328/ https://www.ncbi.nlm.nih.gov/pubmed/35713430 http://dx.doi.org/10.1097/MD.0000000000029252

Ejemplares similares

Efficacy and Safety of Two-Drug Regimens with Dolutegravir plus Rilpivirine or Lamivudine in HIV-1 Virologically Suppressed People Living with HIV
por: Dueñas-Gutiérrez, Carlos, et al.
Publicado: (2023)

Off-label use of rilpivirine in combination with emtricitabine and tenofovir in HIV-1-infected pediatric patients: A multicenter study
por: Falcon-Neyra, Lola, et al.
Publicado: (2016)

Tolerability and effectiveness of albuvirtide combined with dolutegravir for hospitalized people living with HIV/AIDS
por: Liu, Huanxia, et al.
Publicado: (2023)

Viral suppression in the era of transition to dolutegravir-based therapy in Cameroon: Children at high risk of virological failure due to the lowly transition in pediatrics
por: Fokam, Joseph, et al.
Publicado: (2023)

Two case reports of severe myocarditis associated with the initiation of dolutegravir treatment in HIV patients
por: Mahlab-Guri, Keren, et al.
Publicado: (2016)

Predict the Effects of Dolutegravir (DTG) Plus Lamivudine (3TC) on Immunological Responses in People Living with HIV (PLWHIV)
por: Troya, Jesús, et al.
Publicado: (2023)

Case report of Triumeq (abacavir/dolutegravir/lamivudine) associated rhabdomyolysis in a human immunodeficiency virus (HIV) infected patient
por: Saad, Muhammad, et al.
Publicado: (2019)

Real life use of dolutegravir doravirine dual regimen in experienced elderly PLWH with multiple comorbidities and on polypharmacy: A retrospective analysis
por: Mazzitelli, Maria, et al.
Publicado: (2021)

Impact of previous HIV resistance and virologic failures on virologic outcome following a switch to dolutegravir with 2 NRTIs among people living with HIV
por: Sangaré, Mohamed N’dongo, et al.
Publicado: (2020)

Real-world efficacy and safety of dolutegravir plus lamivudine versus tenofovir plus lamivudine and efavirenz in ART-naïve HIV-1-infected adults
por: Li, Jin, et al.
Publicado: (2022)

Effect of Dolutegravir regimen against other regimens on some hematological parameters, CD4 count and viral load of people living with HIV infection in South Eastern Nigeria
por: Echefu, Stella N., et al.
Publicado: (2023)

Dolutegravir Plus 3TC in Virologically Suppressed PLWHIV: Immunological Outcomes in a Multicenter Retrospective Cohort in Spain during the COVID-19 Pandemic
por: Buzón, Luis, et al.
Publicado: (2023)

Reproductive history before and after HIV diagnosis: A cross-sectional study in HIV-positive women in Spain
por: Hernando, Victoria, et al.
Publicado: (2017)

Overall and cause-specific excess mortality in HIV-positive persons compared with the general population: Role of HCV coinfection
por: Alejos, Belén, et al.
Publicado: (2016)

1262. Dolutegravir Plus 3TC In Antiretroviral Experienced Adults: Immunovirological Outcomes In a Multicenter Retrospective Cohort In Spain
por: Buzón-Martín, Luis, et al.
Publicado: (2022)

Integrase strand-transfer inhibitors for treatment of early HIV infection: A case series
por: Teira, Ramón, et al.
Publicado: (2019)

Dolutegravir/rilpivirine for the treatment of HIV-1 infection
por: Dowers, Ellen, et al.
Publicado: (2018)

1598. Predictive equations for immune recovery at 48 weeks of BIC/FTC/TAF treatment in Virologically Suppressed PLWHIV.
por: Tomé, Roberto Pedrero, et al.
Publicado: (2023)

Loss to follow-up and opportunities for reengagement in HIV care in rural Mozambique: A prospective cohort study
por: Fuente-Soro, Laura, et al.
Publicado: (2020)

Observational study to evaluate discontinuation of monotherapy with cobicistat-boosted darunavir in patients with human immunodeficiency virus
por: Solana-Altabella, Antonio, et al.
Publicado: (2022)

Discordant retention of HIV-infected mothers and children: Evidence for a family-based approach from Southern Mozambique
por: Nhampossa, Tacilta, et al.
Publicado: (2020)

New diagnoses of human immunodeficiency virus infection in the Spanish pediatric HIV Cohort (CoRISpe) from 2004 to 2013
por: Jiménez de Ory, Santiago, et al.
Publicado: (2017)

2541. Steady-state PK of Fixed Dose Dolutegravir+Rilpivirine in Hemodialysis
por: Gupta, Samir K, et al.
Publicado: (2023)

Effect of daily consumption of extra virgin olive oil on the lipid profile and microbiota of HIV-infected patients over 50 years of age
por: Olalla, Julián, et al.
Publicado: (2019)

HIV-1 genotypic profiling ensures effective response to third-line antiretroviral therapy in Cameroon
por: Mbouyap, Pretty Rosereine, et al.
Publicado: (2023)

Next-generation sequencing provides an added value in determining drug resistance and viral tropism in Cameroonian HIV-1 vertically infected children
por: Fokam, Joseph, et al.
Publicado: (2018)

Effects of perinatal HIV-infection on the cortical thickness and subcortical gray matter volumes in young adulthood
por: Ruiz-Saez, Beatriz, et al.
Publicado: (2021)

1571. BIC/FTC/TAF in Virologically Suppressed PLWHIV: 48-96 weeks RETROBIC Multicenter Cohort study results.
por: Estévez, Samuel, et al.
Publicado: (2023)

Efavirenz versus boosted atazanavir-containing regimens and immunologic, virologic, and clinical outcomes: A prospective study of HIV-positive individuals
por: Cain, Lauren E., et al.
Publicado: (2016)

Risk factors for infection by oncogenic human papillomaviruses in HIV-positive MSM patients in the ART era (2010–2016)
por: Hidalgo-Tenorio, Carmen, et al.
Publicado: (2017)

Soluble PD-L1: a potential immune marker for HIV-1 infection and virological failure
por: Avendaño-Ortiz, José, et al.
Publicado: (2020)

Vaccination with 10-valent pneumococcal conjugate vaccine in infants according to HIV status
por: Madhi, Shabir A., et al.
Publicado: (2017)

Factors associated with previously undiagnosed human immunodeficiency virus infection in a population of men who have sex with men and male-to-female transgender women in Lima, Peru
por: Billings, Joshua D., et al.
Publicado: (2016)

Serum electrolytes and renal alterations in HIV-seropositive Mexican subjects
por: Garza Tovar, Oscar Antonio, et al.
Publicado: (2021)

2485. Real-world Experience with Dolutegravir Plus Rilpivirine Two-Drug Regimen
por: Ward, Douglas, et al.
Publicado: (2019)

Detection and genotyping of human papillomavirus (HPV) in HIV-infected women and its relationship with HPV/HIV co-infection
por: Badial, Rodolfo Miglioli, et al.
Publicado: (2018)

Perception of quality of care using patient reported experience measures (PREMs) in a cohort of adults with HIV: A cross-sectional study
por: de Lazzari, Elisa, et al.
Publicado: (2022)

Genotypic distribution of HHV-8 in AIDS individuals without and with Kaposi sarcoma: Is genotype B associated with better prognosis of AIDS-KS?
por: Tozetto-Mendoza, Tania Regina, et al.
Publicado: (2016)

Switch to Dolutegravir plus Rilpivirine Dual Therapy in cART-Experienced Subjects: An Observational Cohort
por: Capetti, Amedeo F., et al.
Publicado: (2016)

Switch from tenofovir disoproxil fumarate combination to dolutegravir with rilpivirine improves parameters of bone health
por: McComsey, Grace A., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_3eqncfug7d03lgch4lf753krrg